ClinicalTrials.gg
CompletedNCT00036634Updated Jan 15, 2014

A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients

A Phase 1/2 interventional study of Tenofovir DF and Tenofovir alafenamide in HIV Infections, sponsored by Gilead Sciences. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-01-15.

Sponsored by Gilead Sciences · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 23 studies testing tenofovir alafenamide in HIV Infections — 4 open to participants now, 6 under way, 3 of them phase 3. tenofovir alafenamide · HIV Infections.

Enrollment
21st of 23
30 · median 133
Started
2002
the only one that year
Phase 1/2
Only one
of the 23
Registered
1st of 23
by date
Lead sponsor
12 of 23
Gilead Sciences

Among the 23 studies testing tenofovir alafenamide in HIV Infections, this one is the 21st largest by enrollment, is the only one that started in 2002, is the only one in phase 1/2, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 23 studies testing tenofovir alafenamide in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tenofovir alafenamide

tenofovir alafenamide: first FDA approval 2015 (GENVOYA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing tenofovir alafenamide in HIV Infections, or all of them as a file.
02

Study summary

This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • treatment naive
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 RNA levels greater than or equal to 30,000 copies/mL
  • greater than or equal to 200 cells/mm3
  • Serum creatinine \<1.5 mg/dl
  • Hepatic transaminases less than or equal to 2.5 times the
  • Total less than or equal to 1.5 mg/dL
  • Adequate hematologic function
  • Serum amylase less than or equal to 1.5 times the upper limit of normal
  • Serum phosphate greater than or equal to 2.2 mg/dL
  • Not pregnant

Exclusion criteria

Exclusion Criteria

  • Prior treatment with antiretroviral therapy
  • Immunization within 30 days of study entry
  • A new AIDS defining condition within 30 days of study entry
  • Receiving nephrotoxic agents, probenecid, chemotherapeutic agents, , interleukin-2
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Tenofovir DF

    Participants received tenofovir DF 300 mg for 14 days

    Drug: Tenofovir DF

  • Experimental
    Tenofovir alafenamide 50 mg

    Participants received tenofovir alafenamide 50 mg for 14 days

    Drug: Tenofovir alafenamide

  • Experimental
    Tenofovir alafenamide 150 mg

    Participants received tenofovir alafenamide 150 mg for 14 days

    Drug: Tenofovir alafenamide

Interventions

  • Tenofovir DF tablet administered orally once daily

    Also known as: Viread®

  • Tenofovir alafenamide tablet(s) administered orally once daily

    Also known as: GS-7340

06

What researchers measure

Primary outcomes

  1. Time-weighted average change from baseline through Week 2 (DAVG2) for HIV-1 RNA (log10 copies/mL)

    DAVG2 was defined as the time-weighted average between baseline value through the last available value up to week 2 minus the baseline value.

    Time frame: Baseline to Week 2

Secondary outcomes

  1. Change from baseline in HIV-1 RNA (log10 copies/mL)

    Time frame: Baseline to Week 2

  2. Change from baseline in CD4 cell count (cells/mm3)

    Time frame: Baseline to Week 2

07

Study locations

3 sites
  • Stanford Positive Care Program
    Palo Alto, California 94304, United States
  • Protocare Trials Chicago Center for Clinical Trials
    Chicago, Illinois 60610, United States
  • Rockefeller University Hospital
    New York, New York 10021, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2002, a primary completion of Feb 2003 and a completion of Feb 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2002
First posted
May 14, 2002
Start
Mar 2002
Primary completionActual
Feb 2003
CompletionActual
Feb 2003
Last update
Jan 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00036634
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
May 14, 2002
Start date
Mar 2002
Primary completion
Feb 2003
Completion
Feb 2003
Last update
Jan 15, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion